Objectives:
The aim of our study was to ascertain whether the specific 
INTRODUCTION
Metchnikoff (21) was the first scientist to pinpoint the potential beneficial effects of lactic acid bacteria on the human intestinal flora and their consequences on health. Since that time, a lot of works have been published mainly on the effect of probiotics on digestibility, immunity, protection against diarrhea and it is still a matter of scientific interest at the end of the 20th century (6, 10, 15) even on gastrointestinal diseases (17).
Most of the human trial on probiotics involved fermented dairy products containing various living microorganisms, including bifidobacteria (9, 19) . IDF defined probiotics as "A living microorganism which upon ingestion in certain numbers, exert health benefits beyond inherent basic nutrition" (27).
In order to be active on the intestinal microflora , bifidobacteria have to survive the gastrointestinal environments: aerophilic conditions, acidity of the stomach, bile acids and digestive enzymes aggression. We selected among the Danone collection a resistant strain surviving the passage through the human gastrointestinal tract. tically significant whereas differences in the right and left segment were not (Fig. 2) .
DISCUSSION
The purpose of this work was to determine the effect of a Bifidobacterium fermented milk on colonic transit benefit on colonic transit time was not observed with the heat-treated control, which emphasized the importance of living microorganisms for colonic transit time reduction. The effect on transit time was not observed on all volunteers, and it was more pronounced in women than in men. In fact 5 men and 3 women did not improve their total colonic transit time during Bifidus milk ingestion, and the longer the initial transit time, the greater the reduction after Bifidobacterium DN-173 010 milk ingestion, but this was not statistically significant (data not shown). This suggests that the effect of Bifidobacterium fermented milk on colonic transit time is not an acceleration of all transits but rather a reduction of physiological long transit times, and women were a better target group than men to substantiate this effect. This reduction of the colonic transit time was always within physiological limits, which put this Bifidobacterium fermented milk into the functional probiotic food group (25). Another interesting group could be the elderly as they may have more often slow gut transit time (18, 20) and that improvements by means of fermented milks have been reported (28, 30) .
We can only speculate on the mechanisms of action of this Bifidobacterium DN-173 010 fermented milk on colonic transit time as there were no attempt in this trial to measure any change of the gut flora nor of the flora functionalities because it would have increased the burden of the trial too much. Gut flora is known to interact with gut mucosa by various metabolites such as short chain fatty acids, hydrogen, methane, and many other compounds (2, 12, 23) . In his review Borriello (5) listed the following potential mechanisms: increased colonization, stimulation of cholecystokinin, possible increase of prostaglandin production. decreased metabolism of primary bile acids. Modulation of the activity (3, 7, 9, 19, 29) and composition (6, 14, 29) of the gut flora by ingestion of large number of living bifidobacteria have already been documented. Similar data have been obtained with the strain Bifidobacterium animalis DN-173 010 on the microbial enzyme activities (1, 11) and on the fecal microflora composition (11, 13) . However it is the first time that a functional benefit has been documented in normal human volunteers on total colonic transit time and on the sigmoid stasis of women.
This clinical study reported an improvement within physiological limits of colonic transit time in human volunteers after an 11-day-ingestion of a fermented milk containing living Bifidobacterium DN-173 010. This elicits that specific living strain to be used in some probiotic functional food targeted at the colonic transit function.
CONCLUSION
A milk fermented with Bifidobacterium DN-173 010 was able to shorten colonic transit time in humans, mainly due to improvement of sigmoid transit time. This effect was more prone in the women group, which had slower transit time than men. The selected strain was able to survive the human gut environment and was ingested in a large number of living cultures for eleven days. Using colonic transit time as a global functional marker, this strain had demonstrated a functional benefit. It can then be used in a functional probiotic dairy food, providing that this benefit will remain in a commercially available food. Since the mechanism of action is still unknown, this food should contain a high number of living Bifidobacterium animalis DN-173010 and the benefit must be documented in other human trials.
